These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30777657)

  • 1. Intracerebral haemorrhage during alemtuzumab administration.
    Azevedo CJ; Kutz C; Dix A; Boster A; Sanossian N; Kaplan J
    Lancet Neurol; 2019 Apr; 18(4):329-331. PubMed ID: 30777657
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrent intracerebral hemorrhage due to alemtuzumab treatment in a patient with multiple sclerosis: case report.
    İnci M; Gündüz T; Kürtüncü M; Eraksoy M
    Acta Neurol Belg; 2022 Oct; 122(5):1389-1391. PubMed ID: 35471765
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    Gao J; Jones J; Damato EM; Coles A
    J Neurol; 2019 Jun; 266(6):1539-1540. PubMed ID: 30895387
    [No Abstract]   [Full Text] [Related]  

  • 4. Alemtuzumab in multiple sclerosis: A retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors.
    Bachmann H; Cambron M; Casselman JW; Van Driessche V; Van Haute E; Van Hijfte L; Kelderman T; Hemelsoet D; Laureys G
    Eur J Neurol; 2021 Dec; 28(12):4209-4213. PubMed ID: 34374173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
    Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
    Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab.
    Nerrant E; Thouvenot E; Castelnovo G
    Rev Neurol (Paris); 2017 Mar; 173(3):175-176. PubMed ID: 28320519
    [No Abstract]   [Full Text] [Related]  

  • 7. [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].
    Eichau S; Lopez-Ruiz R; Ruiz-Pena JL; Paramo MD; Navarro-Mascarell G; Izquierdo G
    Rev Neurol; 2018 Jun; 66(11):395-396. PubMed ID: 29790573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
    Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
    Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
    Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
    BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
    John N; Carroll A; Brownlee WJ; Chataway J
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1376-1378. PubMed ID: 31079064
    [No Abstract]   [Full Text] [Related]  

  • 11. Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis.
    Penkert H; Delbridge C; Wantia N; Wiestler B; Korn T
    JAMA Neurol; 2016 Jun; 73(6):757-9. PubMed ID: 27043129
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
    Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
    [No Abstract]   [Full Text] [Related]  

  • 13. Alemtuzumab for the treatment of multiple sclerosis.
    Evan JR; Bozkurt SB; Thomas NC; Bagnato F
    Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
    Saarela M; Senthil K; Jones J; Tienari PJ; Soilu-Hänninen M; Airas L; Coles A; Saarinen JT
    Neurology; 2018 May; 90(18):849-851. PubMed ID: 29602914
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
    Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
    J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
    Metz I; Rieckmann P; Kallmann BA; Brück W
    Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
    [No Abstract]   [Full Text] [Related]  

  • 17. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis.
    Brannigan J; Jones JL; Stacpoole SRL
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32522766
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response.
    Sovetkina A; Nadir R; Scalfari A; Tona F; Murphy K; Rigoni E; Dorsey R; Malik O; Nandoskar A; Singh-Curry V; Nicholas R; Martin N
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32667988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient.
    Baroncini D; Annovazzi P; Guaschino C; Minonzio G; Hametner S; Stadelmann C; Comi G; Ghezzi A; Zaffaroni M
    Mult Scler Relat Disord; 2020 Jun; 41():102061. PubMed ID: 32203930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.